Therapeutics for complex disorders

Because patients can’t wait

OUR MISSION

Transform the paradigm of drug development by clinically derisking new targets using existing drugs.

OUR VISION

All patients have access to safe and effective treatments, no matter how complex or unique their needs.

OUR VALUES

Deep science and urgency drive an ethical and transparent therapeutics revolution

Disrupting Drug Discovery

  • Real Biology from Real Data

    Our discovery starts with patient data powered by AI, using the unique RNA signature of the patient to build an in-silico network using systems biology and our proprietary foundation model of human health. No data? We developed a home collection kit for RNAseq.

  • Effective Treatments & Targets

    We rapidly identify therapeutic mechanisms regardless of root cause of the disease and use our proprietary database to specify molecules to restore health. If needed, we build animal models in a matter of weeks to ask clinically relevant questions about efficacy and safety. Patients can’t wait for decades of basic research.

  • Rapid Clinical Impact

    We derisk discovered therapeutic mechanisms in real patients using the off-target effects of existing drugs, letting us clinically derisk the therapeutic impact of new biology incredibly quickly and efficiently. By prototyping, we can more quickly and inexpensively discover what truly works. This helps patients today, while derisking new therapeutics we develop in parallel.

OUR IMPACT

4

Clinical trials resulting from Unravel’s platform

1

New molecule for Rett syndrome and other disorders

1

FDA Orphan Drug Designation (for Rett syndrome)

4

New therapeutic mechanisms and targets for rare and non-rare complex disorders

Improved patient stratification by drug response over leading AI platforms, validated across 7+ clinical trials

20%

200x

Higher hit rate of in silico predictions compared to phenotypic screening

Unravel Initiates RVL-001 Clinical Program in Colombia for Rett Syndrome With Clinical Trial Tool Translation

George Church, Julie Clauss join Unravel Biosciences advisory board

*

Announcing clinical trial collaboration with Vanderbilt to test RVL001

*

Unravel Initiates RVL-001 Clinical Program in Colombia for Rett Syndrome With Clinical Trial Tool Translation ⋆ George Church, Julie Clauss join Unravel Biosciences advisory board * Announcing clinical trial collaboration with Vanderbilt to test RVL001 *

Subscribe to Unravel's Newsletter

* indicates required

Intuit Mailchimp